- Citations, last 5 years
- 42
- Works, last 5 years
- 1
- h-index
- 22
- Scientists listed
- 0
- Grants since 2016
- 16
Grants received
2020–2025 · grant · PRMRP
ARF6 Inhibitor for Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome
Alan Mueller · Navigen (United States) · funded by Congressionally Directed Medical Research Programs
2019–2021 · research · R43
Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2018–2019 · research · R43
ARF6 Inhibitor as Adjunctive Therapy for Treatment of SA Bacteremia
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease
Brett D Welch · Navigen (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease
Brett D Welch · Navigen (United States) · funded by National Institutes of Health
2017–2020 · research · R01
Depot formulation of a D-peptide HIV entry inhibitor
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2017–2020 · research · R01
Depot formulation of a D-peptide HIV entry inhibitor
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2017–2018 · research · R43
D-peptide inhibitors of SIRPα anti-phagocytic signaling
James Nicholas Francis · Navigen (United States) · funded by National Institutes of Health
2017–2020 · research · R01
Depot formulation of a D-peptide HIV entry inhibitor
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2016–2017 · research · R56
Depot formulation of a D-peptide HIV entry inhibitor
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2011–2020 · grant · SB1
Therapeutic D-peptide Inhibitor of HIV Entry
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2011–2020 · grant · SB1
Therapeutic D-peptide Inhibitor of HIV Entry
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2011–2023 · cooperative agreement · U44
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2011–2020 · grant · SB1
Therapeutic D-peptide Inhibitor of HIV Entry
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2011–2023 · cooperative agreement · U44
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health
2011–2023 · cooperative agreement · U44
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV
Alan L Mueller · Navigen (United States) · funded by National Institutes of Health